Aldeyra CEO buys 250,000 ALDX shares

Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady reported an open-market purchase of common stock.

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady reported an open-market purchase of common stock. He bought 250,000 shares of Aldeyra common stock at a weighted average price of $1.6738 per share in transactions on June 3, 2026. Following this purchase, he directly owns 1,721,298 shares of Aldeyra common stock. The footnote explains that the shares were acquired in multiple trades at prices ranging from $1.64 to $1.70 per share.

Insider Trade Summary

Net Buyer: 250,000 shares

Net Buy 1 txn

Insider Brady Todd C

Role President and CEO

Bought 250,000 shs ($418K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	250,000	$1.6738	$418K

Holdings After Transaction: Common Stock — 1,721,298 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

Key Figures

Shares purchased: 250,000 shares Weighted average price: $1.6738 per share Post-transaction holdings: 1,721,298 shares +2 more

5 metrics

Shares purchased 250,000 shares Open-market common stock purchase on June 3, 2026

Weighted average price $1.6738 per share Average purchase price across multiple trades

Post-transaction holdings 1,721,298 shares Direct ownership after the reported purchase

Price range of trades $1.64–$1.70 per share Range of individual trade prices in the purchase

Net buy shares 250,000 shares Net buy direction in transaction summary

Key Terms

open-market purchase, weighted average price, direct ownership

3 terms

open-market purchase financial

"transaction_action: "open-market purchase" for the common stock acquisition"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

direct ownership financial

"total_shares_following_transaction ... ownership_type: "direct""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aldeyra Therapeutics (ALDX) report for Todd C. Brady?

Aldeyra’s President and CEO, Todd C. Brady, reported an open-market purchase of 250,000 shares of common stock. The trade occurred on June 3, 2026, and was reported on Form 4 as a direct ownership transaction.

At what price did Aldeyra Therapeutics (ALDX) CEO buy shares on June 3, 2026?

The CEO bought Aldeyra shares at a weighted average price of $1.6738 per share. Individual trades were executed in a range from $1.64 to $1.70, as disclosed in the Form 4 footnote.

How many Aldeyra Therapeutics (ALDX) shares does the CEO own after this Form 4 trade?

After the reported purchase, Aldeyra’s CEO directly owns 1,721,298 shares of common stock. This figure reflects his holdings immediately following the 250,000-share open-market acquisition disclosed in the Form 4.

Was the Aldeyra Therapeutics (ALDX) CEO transaction an open-market purchase?

Yes. The Form 4 describes the transaction as an open-market purchase of common stock, coded as “P,” meaning the shares were acquired through market or private transactions rather than as a grant or option exercise.

What price range is disclosed for the Aldeyra Therapeutics (ALDX) CEO’s share purchases?

The filing notes that shares were acquired in multiple trades at prices ranging from $1.64 to $1.70 per share. The reported $1.6738 figure is a weighted average across those individual transactions, according to the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brady Todd C

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		P		250,000	A	$1.6738(1)	1,721,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

	/s/ Todd C. Brady	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)